Stay updated on Tepotinib & Gefitinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.

Latest updates to the Tepotinib & Gefitinib in NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov page’s displayed site revision advances from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check12 days agoChange DetectedThe clinical trial record for the Tep ಸೆotinib–gefitinib NSCLC study is available, including its completed status, eligibility criteria, treatment arms, outcomes, and study locations; it previously showed an access-denied error.SummaryDifference94%

- Check19 days agoChange DetectedThe ClinicalTrials.gov page’s displayed site revision changed from v3.7.2 to v3.8.0. The study record itself still shows a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedAn NIH-wide banner announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1 on the error page.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error, effectively blocking access to the study record. Most study-related navigation and document links appear to have been removed.SummaryDifference21%

Stay in the know with updates to Tepotinib & Gefitinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.